RICHARDSON, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) — On August 14, 2023, Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, filed its quarterly report on Form 10-Q for the quarter ended June 30, 2023 with the Securities and Exchange Commission (“SEC”).
Second Quarter 2023 Financial Highlights
Christopher C. Reeg, Chief Executive Officer of Fuse Medical, commented, “We are pleased with our second quarter performance, as highlighted by a 7% increase in revenue, a 31% increase in gross profit, and a $648,408 increase in EBITDA over the prior-year period. Our implementation and achievement of strategic initiatives, which includes increasing our portfolio of Fuse branded and manufactured products, is reflected in our second quarter results.”
Mr. Reeg further added, “Our growth for the remainder of 2023, and into 2024 is focused on continued design and development of unique medical devices for commercialization, new product launches in the orthopedics and spine marketplace, and expansion of our national distribution footprint. We expect the execution of these strategic initiatives to drive growth in the near term, while increasing our visibility as an emerging manufacturer of relevant medical devices.”
About Fuse Medical, Inc.
Fuse is an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace. We provide a comprehensive portfolio of products in the orthopedic total joints, sports medicine, trauma, foot and ankle space, as well as, degenerative and deformity spine, osteobiologics, wound care, and regenerative products. For more information about the Company, or if you’re interested in becoming a distributor of any Fuse’s products, please contact us at info@fusemedical.com or visit: www.fusemedical.com.
Forward Looking Statements
Certain statements in this press release, constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the Securities and Exchange Commission; the failure of the Company to close the transaction; and integration issues with the consolidated company. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.
Note Regarding Use of Non-GAAP Financial Measurements:
The financial data contained in this press release includes certain non-GAAP financial measures as defined by the Securities and Exchange Commission (“SEC”), including “EBITDA”. The Company is presenting EBITDA because it believes that it provides useful information to investors about Fuse, its business and its financial condition. The Company defines EBITDA as net income or loss from continuing operations before the effects of interest expense, taxes, depreciation and amortization. The Company believes EBITDA is useful to investors because it is one of the measures used by the Company’s Board of Directors and management to evaluate its business, including in internal management reporting, budgeting and forecasting processes, in comparing operating results across the business, as an internal profitability measure, as a component in evaluating the ability and the desirability of making capital expenditures and significant acquisitions, and as an element in determining executive compensation.
However, EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America (“GAAP”), and the items excluded from EBITDA are significant components in understanding and assessing financial performance. Therefore, EBITDA should not be considered a substitute for net income (loss) or cash flows from operating, investing, or financing activities. Because EBITDA is calculated before recurring cash charges including interest expense and taxes, and is not adjusted for capital expenditures or other recurring cash requirements of the business, it should not be considered as a measure of discretionary cash available to invest in the growth of the business. There are a number of material limitations to the use of EBITDA as an analytical tool, including the following:
The Company compensates for these limitations by relying primarily on its GAAP financial measures and by using EBITDA only as supplemental information. The Company believes that consideration of EBITDA, together with a careful review of its GAAP financial measures, is the most informed method of analyzing Fuse Medical, Inc.
The Company reconciles EBITDA to net income, and that reconciliation is set forth below. Because EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
| FUSE MEDICAL, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (in dollars, except share data) | ||||||||
| June 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | 253,378 | $ | 147,854 | ||||
| Accounts receivable, net of allowance of $200,798 and $290,500, respectively | 3,433,900 | 3,996,860 | ||||||
| Inventories, net of allowance of $1,521,421 and $1,778,173, respectively | 9,026,923 | 9,494,506 | ||||||
| Prepaid expenses and other current assets | 104,363 | 126,022 | ||||||
| Total current assets | 12,818,564 | 13,765,242 | ||||||
| Property and equipment, net | – | 709 | ||||||
| Long term accounts receivable, net of allowance of $5,172,858 and $4,330,883, respectively | 3,401,297 | 2,832,764 | ||||||
| Intangible assets, net | 1,125,549 | 1,190,980 | ||||||
| Goodwill | 1,972,886 | 1,972,886 | ||||||
| Total assets | $ | 19,318,296 | $ | 19,762,581 | ||||
| Liabilities and Stockholders’ Equity (Accumulated Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,238,209 | $ | 5,700,236 | ||||
| Accrued expenses | 5,605,104 | 4,540,366 | ||||||
| Notes payable – related parties | 350,000 | 150,000 | ||||||
| Senior secured revolving credit facility | 1,870,912 | 1,997,135 | ||||||
| Total current liabilities | 12,064,225 | 12,387,737 | ||||||
| Notes payable – related parties | – | 200,000 | ||||||
| Earn-out liability | 7,485,698 | 7,485,698 | ||||||
| Total liabilities | 19,549,923 | 20,073,435 | ||||||
| Commitments and contingencies | – | – | ||||||
| Stockholders’ equity (accumulated deficit) | ||||||||
| Preferred stock, $0.01 par value; 20,000,000 shares authorized, no shares issued and outstanding | – | – | ||||||
| Common stock, $0.01 par value; 100,000,000 shares authorized, 73,895,794 shares issued and outstanding as of June 30, 2023 and December 31, 2022 | 738,958 | 738,958 | ||||||
| Additional paid-in capital | 1,468,274 | 1,468,274 | ||||||
| Accumulated deficit | (2,438,859 | ) | (2,518,086 | ) | ||||
| Total stockholders’ equity (accumulated deficit) | (231,627 | ) | (310,854 | ) | ||||
| Total liabilities and stockholders’ equity (accumulated deficit) | $ | 19,318,296 | $ | 19,762,581 | ||||
| FUSE MEDICAL, INC. | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| (in dollars, except share data) | ||||||||||||||||
| For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
|||||||||||||||
| 2023 | 2022 Revised |
2023 | 2022 Revised |
|||||||||||||
| Net revenues | $ | 4,997,212 | $ | 4,668,290 | $ | 8,981,667 | $ | 9,222,628 | ||||||||
| Cost of revenues | 1,528,321 | 2,028,497 | 2,696,723 | 3,771,806 | ||||||||||||
| Gross profit | 3,468,891 | 2,639,793 | 6,284,944 | 5,450,822 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general, administrative and other | 1,618,160 | 1,422,768 | 3,324,487 | 3,132,309 | ||||||||||||
| Commissions | 1,449,157 | 1,463,859 | 2,691,034 | 2,969,530 | ||||||||||||
| Depreciation and amortization | 32,715 | 34,404 | 66,140 | 68,806 | ||||||||||||
| Total operating expenses | 3,100,032 | 2,921,031 | 6,081,661 | 6,170,645 | ||||||||||||
| Operating (loss) profit | 368,859 | (281,238 | ) | 203,283 | (719,823 | ) | ||||||||||
| Other (income) expense: | ||||||||||||||||
| Interest expense | 54,024 | 36,527 | 111,217 | 69,485 | ||||||||||||
| Total other (income) expense | 54,024 | 36,527 | 111,217 | 69,485 | ||||||||||||
| Net income (loss) before income tax | 314,835 | (317,765 | ) | 92,066 | (789,308 | ) | ||||||||||
| Income tax expense | 7,247 | 5,171 | 12,839 | 10,027 | ||||||||||||
| Net income (loss) | $ | 307,588 | $ | (322,936 | ) | $ | 79,227 | $ | (799,335 | ) | ||||||
| Net income (loss) per common share – basic and diluted | $ | 0.00 | $ | (0.00 | ) | $ | 0.00 | $ | (0.01 | ) | ||||||
| Weighted average number of common shares outstanding – basic | 70,321,566 | 70,321,566 | 70,321,566 | 70,321,566 | ||||||||||||
| Weighted average number of common shares outstanding – diluted | 75,976,582 | 70,321,566 | 75,976,582 | 70,321,566 | ||||||||||||
| Supplemental Non-GAAP Disclosure | |||||||||||||||
| EBITDA | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended June 30, |
For the Six Months Ended June 30, |
||||||||||||||
| 2023 | 2022 Revised | 2023 | 2022 Revised | ||||||||||||
| Net income (loss) | $ | 307,588 | $ | (322,936 | ) | $ | 79,227 | $ | (799,335 | ) | |||||
| Add (Deduct): | |||||||||||||||
| Income tax expense (benefit) | 7,247 | 5,171 | 12,839 | 10,027 | |||||||||||
| Interest expense | 54,024 | 36,527 | 111,217 | 69,485 | |||||||||||
| Depreciation and amortization | 32,715 | 14,493 | 66,140 | 68,806 | |||||||||||
| EBITDA | $ | 401,574 | $ | (266,745 | ) | $ | 269,423 | $ | (651,017 | ) | |||||
| FUSE MEDICAL, INC. | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (unaudited) | ||||||||
| For the Six Months Ended June 30, | ||||||||
| 2023 | 2022 Revised | |||||||
| Cash flows from operating activities | ||||||||
| Net income (loss) | $ | 79,227 | $ | (799,335 | ) | |||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 66,140 | 68,806 | ||||||
| Stock based compensation | – | 16,946 | ||||||
| Provision for bad debts and discounts | (89,703 | ) | (102,595 | ) | ||||
| Provision for long term accounts receivable | 841,975 | 402,200 | ||||||
| Provision for slow moving inventory | (256,752 | ) | (94,595 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 652,663 | 666,843 | ||||||
| Inventories | 724,335 | (526,213 | ) | |||||
| Prepaid expenses and other current assets | 21,659 | (89,410 | ) | |||||
| Long term accounts receivable | (1,410,508 | ) | (670,332 | ) | ||||
| Accounts payable | (1,462,027 | ) | 320,071 | |||||
| Accrued expenses | 1,064,738 | 1,055,519 | ||||||
| Net cash provided by operating activities | 231,747 | 247,905 | ||||||
| Cash flows from investing activities | ||||||||
| Purchase of property and equipment | – | – | ||||||
| Net cash (used in) investing activities | – | – | ||||||
| Cash flows from financing activities | ||||||||
| Net payments on senior secured revolving credit facility | (126,223 | ) | (197,099 | ) | ||||
| Net cash (used in) financing activities | (126,223 | ) | (197,099 | ) | ||||
| Net increase (decrease) in cash | 105,524 | 50,806 | ||||||
| Cash and cash equivalents – beginning of period | 147,854 | 553,190 | ||||||
| Cash and cash equivalents – end of period | $ | 253,378 | $ | 603,996 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | 92,833 | $ | 50,796 | ||||
Contact:
Fuse Medical, Inc.
Attention: Lawrence Yellin, CFO
1565 North Central Expressway, Suite 220
Richardson, Texas 75080
Office (469) 862-3030
Facsimile (469) 862-3035
info@Fusemedical.com
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…
This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…